

**ACCESSION NUMBER: F10-10298**

**PATIENT: Doe, John**

**Physician:** John Nice, M.D.

**D.O.B.** 11/25/1932 **AGE:** 77 yrs **SEX:** M

**Facility:** Best Clinic  
1212 Main St.  
Good Town IN 46321

**Specimen Type:** Bone Marrow  
**Date Collected:** 04/06/2010  
**Date Received:** 04/07/2010  
**Date Reported:** 04/09/2010

**Facility MR #** 1234567

**Clinical History:**

Thrombocytopenia (287.5),Leukopenia (288.50)/MDS

**FISH REPORT**


<b>RESULT:</b>	<b>Bone Marrow: Positive FISH Study for Deleted 5q, Trisomy 8, and Trisomy D13S319, See Interpretation.</b>
<b>DESIGNATION:</b>	nuc ish (CSF1Rx1)[170/200], (D7S486x2), (D8Z2x3)[135/200], (ETOx3)(RUNX1x2)[142/200], (MLLx2), (D13S319x3)(LAMP1x2)[54/200], (PML,RARA)x2, (CBFBx2), (D20S108x2)[200]

**Indication for study:**

Thrombocytopenia (287.5),Leukopenia (288.50)/MDS

**Interpretation:**

Probe panels for MDS and AML were used on interphase nuclei, all were negative except Deleted 5q, Trisomy 8, and Trisomy D13S319(13q14.3). Deletion 5q was seen in 170(85%) of 200 cells counted. Deletion of 5q is a common finding in myeloid disorders (MDS, MPD, and AML). Trisomy 8 was seen in 135(67.5 %) of 200 cells counted. An extra ETO(8q22) signal was seen in 142(71.0%) of 200 cells counted. Trisomy 8 is most common non-specific finding in myeloid disorders. It occurs in 20-30% of all MDS and in 10-15% all AML cases. Trisomy of 13q14.3 was seen in 54(27%) of 200 cells counted. Trisomy 13 is found in 2-3% of AML with other chromosomal abnormalities. These results portend unfavorable prognosis.



Deleted 5q33-34

<b>5q33q34 locus</b>	<b>Positive/Deleted (85.0% of 200 cells counted)</b>
<b>7q31 locus</b>	<b>Negative (200 cells counted)</b>
<b>8cen locus</b>	<b>Positive/Trisomy (67.5% of 200 cells counted)</b>
<b>8q22/21q22 (ETO/RUNX1)</b>	<b>Positive/Trisomy (71.0% of 200 cells counted)</b>
<b>11q23 (MLL)</b>	<b>Negative (200 cells counted)</b>
<b>13q14.3/13q34 (D13S319/LAMP1)</b>	<b>Positive/Trisomy(27.0% of 200 cells counted)</b>
<b>15q22/17q21(PML/RARA)</b>	<b>Negative (200 cells counted)</b>
<b>16q22(CBFB)</b>	<b>Negative (200 cells counted)</b>
<b>20q12 locus</b>	<b>Negative (200 cells counted)</b>

Electronic Signature

This test was developed and its performance characteristics determined by Hematogenix Laboratory Services. It has not been cleared or approved by the Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is for clinical use and should not be viewed as experimental or for research use only.